Low aBMD is prevalent in FRDA, but few of even the highest risk individuals are undergoing screening. Our findings highlight potential missed opportunities for the screening and treatment of low aBMD in FRDA.
Tuesday, March 15, 2022
Bone Mineral Density and Current Bone Health Screening Practices in Friedreich’s Ataxia
Dunn J, Tamaroff J, DeDio A, Nguyen S, Wade K, Cilenti N, Weber DR, Lynch DR and McCormack SE (2022) Bone Mineral Density and Current Bone Health Screening Practices in Friedreich’s Ataxia. Front. Neurosci. 16:818750. doi: 10.3389/fnins.2022.818750
Friedreich’s Ataxia Related Diabetes: Epidemiology and Management Practices
Jaclyn Tamaroff, Anna DeDio, Kristin Wade, McKenzie Wells, Courtney Park, Karla Leavens, Christian Rummey, Andrea Kelly, David R. Lynch, Shana E. McCormack; Diabetes Research and Clinical Practice, 2022,
109828, doi.org/10.1016/j.diabres.2022.109828.
FRDA-related DM was reported by 8.7% of individuals. Age, severe disease, and FRDA cardiac complications were positively associated with DM risk. FRDA-related DM was generally well-controlled, as reflected by HbA1c, though diabetic ketoacidosis did occur. Insulin is the mainstay of treatment (64-74% overall); in adults, metformin use was common, and newer glucose-lowering agents were used rarely.
Subscribe to:
Posts (Atom)
